DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd has a price-to-earnings (PE) ratio of 14.0 in the Healthcare sector.

What is the market capitalisation of Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd has a market capitalisation of approximately ₹484 crore.

Jenburkt Pharmaceuticals Ltd

JENBURKTPHARMACEUTICALSLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

52W₹944

₹1400-207%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹484 Cr

P/E Ratio

14.00Cheap

P/B Ratio

2.47

EPS

₹72.64

Book Value

₹446.48

ROE

20.40%Strong

ROCE

27.00%Efficient

Dividend Yield

1.63%

Debt / Equity

0.01Low

Face Value

₹10.00

52W High

₹1400.00

52W Low

₹944.00

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

Narrow moatMedium uncertainty

Fair value estimate

₹640

No recent traded price

BearFair valueBull

₹544₹640₹799

/100

Business quality — Solid

Growth 50Profitability 89Efficiency 95Valuation 95

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Strong returns on equity (20%)
Capital is working hard (ROCE 27%)
Reasonably priced at 14× earnings

How we got there

Fair value methods

Residual income

19% ROE fading to 12% over ~10 yrs, on ₹446 book

₹596

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹799

Analyst target

No analyst coverage

—

Blended fair value₹640

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (20%)
Capital is working hard (ROCE 27%)
Reasonably priced at 14× earnings

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

14.0Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

20.4%Strong

Above 15% is considered healthy for Indian equities

ROCE

27.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹484 Cr

P/B

2.47

EPS

₹72.64

Div Yield

1.63%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 14.0×

Growth

Steady

+7% rev CAGR

Profitability

Excellent

20.4% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+7.2%

+9.1%

10Y

+6.0%

Profit

+10.7%

+16.2%

10Y

+11.9%

EPS

+4.4%

+12.1%

10Y

+10.6%

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 25.7%

Watch-outs

Cons

The company has delivered a poor sales growth of 9.08% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

47%

Promoter

Promoters

46.6%-0.01

Public

41.0%-2.10

FII / FPI

0.0%0.00

DII

0.1%0.00

Others

12.2%

Total shareholders

6,999-164 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter46.64%

DII0.12%

Public41.03%

Others12.21%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]